New partnership agreement with Capebio

New partnership agreement with Capebio

Trieste, January 29th 2025 - Ulisse Biomed announces that it has signed a new partnership agreement with Capebio.

Capebio is a South African company, a leader in the biotech field, with strong R&D capabilities to commercialization of molecular biology diagnostic tests.

The agreement firstly provides for the commercialization of Ulisse Biomed's proprietary solutions for HPV screening and genotyping, as well as the Hyris System™, a proprietary hardware and software platform for genetic analysis.

The agreement is exclusive to the Southern African market.

“We are proud to initiate this commercial relationship with CapeBIO, in order to develop the Southern African market with such an innovative partner” says Gabriele Salaris, Head of Marketing & Sales at Ulisse Biomed. “Our goal is to start from the commercialization of our existing solutions for HPV screening and testing, but we already foresee great opportunities in potentially going further, collaborating in the development of new tests that will fit the African market needs” concludes Salaris.

“This partnership is long-term and echoes our strategic goals of harnessing international partner technologies to boost our immediate market offerings, creating a critical mass of technologies that blend with our current offerings. We also look forward to exchanging the two companies’ R&D capabilities, the know-hows and efforts to accelerate high-impact innovations and their commercializaiton,” adds Daniel Ndima, CEO at Capebio.